A Phase II Study Evaluating the Combination of Neratinib Plus Trastuzumab or Neratinib Plus Cetuximab in Patients with "Quadruple Wild-Type" (KRAS/NRAS/BRAF/PIK3CA Wild-Type) Metastatic Colorectal Cancer Based on HER2 Status: Amplified, Non-Amplified (Wild-Type) or Mutated
Protocol Chair: Samuel Jacobs, MD
Protocol Officer: Carmen Allegra, MD
Primary Objective: To determine the progression-free survival (PFS) in each of these HER2 populations.
Patient Population: "quadruple wild-type" (all RAS/NRAS/BRAF/PIK3CA wild-type), metastatic colorectal cancer based on HER2 status (amplified, non-amplified [wild-type] or mutated).
Target Accrual: 35 patients
Status: Recruiting participants
ClinicalTrials.gov Identifier: NCT03457896
The Mission of NSABP Foundation, Inc. is to design and conduct practice changing cancer research, including clinical trials and laboratory studies in the medical, surgical and prevention settings in order to improve the survival outcome and quality of life of patients with breast and colorectal cancer, and to disseminate the results of NSABP collaborative research to benefit the world-wide community.
NSABP Foundation Inc.
Nova Tower 2
Two Allegheny Center – Suite 1200
Pittsburgh, PA 15212-5402